COPD drugs is a medicine used to treatment chronic obstructive pulmonary disease, such as bronchodilators, pde-4 inhibitors_ steroids, combination therapies, etc.
Scope of the Report:This report studies the COPD Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the COPD Drugs market by product type and applications/end industries.
One of the emerging trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to treat COPD. Combination therapies are increasingly becoming the preferred choice of treatment as they have better efficacy than monotherapy drugs.
The bronchodilators segment is one of the fastest growing segments of the COPD drugs market. Bronchodilators help relax bronchial muscles resulting in normal breathing. These drugs can be categorized into three types, namely beta-sympathomimetic, anticholinergics, and xanthine derivatives.
The global COPD Drugs market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of COPD Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers Pfizer
Novartis
GlaxoSmithKline
Merck
Abbott Laboratories
Boehringer Ingelheim
AstraZeneca
Roche Holding AG
Teva Pharmaceutical Industries
Vectura Group
Mylan NV
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers Bronchodilators
PDE-4 Inhibitors
Steroids
Combination Therapies
Others
Market Segment by Applications, can be divided into Hospitals
Clinics
Others
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
